Arrowhead Pharmaceuticals vs Travere Therapeutics
ARWR and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARWR and TVTX compare
Arrowhead Pharmaceuticals is the larger company, worth 1.4 times as much as Travere Therapeutics ($6.7B against $4.8B).
Travere Therapeutics grew revenue faster over the last twelve months (49.4% versus −45.6% for Arrowhead Pharmaceuticals).
Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −18.7% compared with −161% at Arrowhead Pharmaceuticals.
Travere Therapeutics scores higher on the StockData Score (6 against 3 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARWR | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $6.7B | $4.8B |
| Share price | $47.78 | $50.65 |
| Change, 1 year | 15.4% | 38.9% |
| Change, 5 years | −32.8% | 73.0% |
| Beta (5Y) | 1.68 | 1.14 |
| Employees | 711 | 497 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.0× | 7.3× (better) |
| P/B | 134× (better) | 211× |
| FCF yield | −4.2% | – |
| Growth | ||
| Revenue growth (TTM) | −45.6% | 49.4% (better) |
| Revenue growth, 5Y average | 26.7% (better) | 19.9% |
| Profitability | ||
| Gross margin | – | 98.5% |
| Operating margin | −157% | −20.5% (better) |
| Net margin | −161% | −18.7% (better) |
| FCF margin | −63.0% | – |
| Return on equity | −281% | −253% (better) |
| Financial health | ||
| Interest coverage | −7.5× (better) | −15.1× |
| Current ratio | 4.14 (better) | 3.00 |
| Altman Z-score | 0.10 | 1.68 (better) |
| Piotroski F-score | 2 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.6% | 112% |
| Held by insiders | 4.0% | 1.6% |
| Insider net buying, 12 months | −$36.9M (better) | −$110M |
| Short interest, % of float | 8.5% | 10.3% |
Go deeper
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.